Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

被引：44
|
作者：
Schoenfeld, Kurt [1 ]
Zuber, Chantal [1 ]
Pinkas, Jan [2 ]
Haeder, Thomas [1 ]
Bernoester, Katrin [1 ]
Uherek, Christoph [1 ]
机构：
[1] Biotest AG, Landsteinerstr 5, D-63303 Dreieich, Germany
[2] ImmunoGen Inc, 830 Winter St, Waltham, MA 02451 USA
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2017年 / 10卷
关键词：
Multiple myeloma; Pre-clinical; Indatuximab ravtansine; Drug combination; Tumour regression; AGENTS;
D O I：
10.1186/s13045-016-0380-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/ dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] An antisense platform for the pre-clinical development of novel LncRNA inhibitors in multiple myeloma
    Morelli, Eugenio
    Gulla, Annamaria
    Liu, Na
    Johnstone, Megan
    Vinaixa, Delaney
    Gramegna, Doriana
    Wen, Kenneth
    Tai, Yu-Tzu
    Chauhan, Dharminder
    Samur, Mehmet
    Shammas, Masood
    Fulciniti, Mariateresa
    Gryaznov, Sergei
    Anderson, Kenneth
    Munshi, Nikhil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S94 - S95
  • [22] PRE-CLINICAL STUDIES OF DYNAMIC TREATMENT MODES IN PION THERAPY
    AMOLS, HI
    KITTELL, R
    PACIOTTI, MA
    HELLEND, JA
    HOGSTROM, KR
    COLLIER, M
    HELLER, P
    MEDICAL PHYSICS, 1980, 7 (06) : 621 - 626
  • [23] Pre-clinical evaluation of candidate antibodies for targeted radiotherapy for patients with multiple myeloma.
    Orchard, KH
    Cooper, MS
    Wijdenes, J
    Borchardt, P
    Quadri, SM
    Buscombe, JR
    Hilson, AJ
    Mehta, A
    Prentice, HG
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 117P - 118P
  • [24] Fc Receptor Targeting Reduces Bone Disease in a Pre-Clinical Model of Multiple Myeloma
    Williams, Mark T.
    Thuemmler, Katya
    Kitson, Susan
    Soutar, Richard
    Goodyear, Carl S.
    BLOOD, 2015, 126 (23)
  • [25] Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma
    Turner, Joel G.
    Dawson, Jana L.
    Sullivan, Daniel M.
    CANCER RESEARCH, 2016, 76
  • [26] Studies of the Bcl inhibitor GX15-070 in multiple myeloma demonstrate substantial pre-clinical activity.
    Stewart, AK
    Li, ZH
    Wen, XY
    Rauw, J
    Pathangey, L
    Bergsagel, PL
    Trudel, S
    BLOOD, 2005, 106 (11) : 451A - 451A
  • [27] Investigation of the robustness of twomodels for assessing synergy in pre-clinical drug combination studies
    Whitehead, Anne
    Su, Ting-Li
    Thygesen, Helene
    Sperrin, Matthew
    Harbron, Chris
    PHARMACEUTICAL STATISTICS, 2013, 12 (05) : 300 - 308
  • [28] Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
    Drent, Esther
    Groen, Richard W. J.
    Noort, Willy A.
    Themeli, Maria
    van Bueren, Jeroen J. Lammerts
    Parren, Paul W. H. I.
    Kuball, Jurgen
    Sebestyen, Zsolt
    Yuan, Huipin
    de Bruijn, Joost
    van de Donk, Niels W. C. J.
    Martens, Anton C. M.
    Lokhorst, Henk M.
    Mutis, Tuna
    HAEMATOLOGICA, 2016, 101 (05) : 616 - 625
  • [29] Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)
    Adamia, Sophia
    Bhatt, Shruti
    Tai, Yu-Tzu
    Wen, Kenneth
    Nicholas, Catherine A.
    Pioso, Marissa S.
    Abiatari, Ivane
    Letai, Anthony G.
    Anderson, Kenneth
    BLOOD, 2020, 136
  • [30] Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma
    Rychak, Emily
    Mendy, Derek
    Shi, Tao
    Ning, Yuhong
    Leisten, Jim
    Lu, Ling
    Miller, Karen
    Narla, Rama K.
    Orlowski, Robert Z.
    Raymon, Heather K.
    Bjorklund, Chad C.
    Thakurta, Anjan
    Gandhi, Anita K.
    Cathers, Brian E.
    Chopra, Rajesh
    Daniel, Thomas O.
    Lopez-Girona, Antonia
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (06) : 889 - 901
12345